<DOC>
	<DOCNO>NCT02570984</DOCNO>
	<brief_summary>This trial randomize , double-blind , placebo control trial design test whether two year treatment preschool child age 2-3 year age high risk asthma omalizumab ( anti-IgE ) two year prevent progression childhood asthma , reflect reduction prevalence active asthma Final 12 month 2 year observation period study drug .</brief_summary>
	<brief_title>Controlling Preventing Asthma Progression Severity Kids</brief_title>
	<detailed_description>Prevention/ Disease modification asthma .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>2447 month randomization positive allergy aeroallergen 12 wheeze episode past year chronic lung disease besides asthma allergy study medication</criteria>
	<gender>All</gender>
	<minimum_age>24 Months</minimum_age>
	<maximum_age>47 Months</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>